2012
DOI: 10.3748/wjg.v18.i12.1391
|View full text |Cite
|
Sign up to set email alerts
|

Opiate-induced constipation related to activation of small intestine opioid μ2-receptors

Abstract: Loperamide induces intestinal relaxation by activation of opioid μ-2 receptors via the cAMP-PKA pathway to open K(ATP) channels, relates to OIC.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

3
21
0

Year Published

2013
2013
2024
2024

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 34 publications
(24 citation statements)
references
References 30 publications
3
21
0
Order By: Relevance
“…The reduction of body weight induced by opioid and tramadol was attributed to the reduction of androgen synthesis that might be associated with reduction of its metabolism (Yilmaz et al, 1999) and to the major metabolite of tramadol (O-desmethyl tramadol) that affects the intestinal motility and inhibited peristalsis of small intestine more than the parent compound (Herbert et al, 2007). Moreover, presence of μ-opioid receptors in the intestinal tract that leads to inhibition of the peristaltic action (Chen et al, 2012).…”
Section: Discussionmentioning
confidence: 99%
“…The reduction of body weight induced by opioid and tramadol was attributed to the reduction of androgen synthesis that might be associated with reduction of its metabolism (Yilmaz et al, 1999) and to the major metabolite of tramadol (O-desmethyl tramadol) that affects the intestinal motility and inhibited peristalsis of small intestine more than the parent compound (Herbert et al, 2007). Moreover, presence of μ-opioid receptors in the intestinal tract that leads to inhibition of the peristaltic action (Chen et al, 2012).…”
Section: Discussionmentioning
confidence: 99%
“…Loperamide is a popularly prescribed to reduce the bowel motility that causes diarrhea. It induces intestinal relaxation by activating opioid μ2 receptors via the cAMP-PKA pathway, which in turn prevents the exocytosis of acetylcholine from the parasympathetic nerves of the ileum, as demonstrated in mice (Chen et al 2012). In the large intestine, Lop suppresses the release of 5-hydroxytryptamine (5-HT), an enhancer of colonic motility, from the colonic mucosa, in a process triggered by the NK3 receptor, probably by activating κ-and δ-opioid receptors, as shown in guinea pigs (Kojima et al 2005).…”
Section: Groupmentioning
confidence: 99%
“…This lack of tolerance differs from other adverse effects of opioid analgesics and could possibly be related to the actions associated with μ-opioid receptor subtypes (eg, tolerance develops for activities that are μ-1 dependent versus other subtypes). [26][27][28] Given the lack of tolerance development to OIC, it is important that OIC be anticipated and be treated as appropriate in patients receiving opioid analgesics. 4 The strength of this placebo crossover analysis is that the design allowed patients to serve as their own controls when comparing the efficacy and safety of methylnaltrexone versus placebo.…”
Section: Discussionmentioning
confidence: 99%